The effect of renin–angiotensin–aldosterone system inhibitors in patients with hypertension and COVID-19: A meta-analysis of randomized controlled trials and propensity score-matched studies

BACKGROUND: High-quality evidence for whether the use of renin–angiotensin–aldosterone system (RAAS) inhibitors worsens clinical outcomes for patients with coronavirus disease 2019 (COVID-19) is lacking. The present study aimed to evaluate the effect of RAAS inhibitors on disease severity and mortal...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhang, Kai, Cao, Lanxin, Xuan, Nanxia, Huang, Tiancha, Tian, Baoping, Cui, Wei, Zhang, Gensheng, Zhang, Shufang
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2022
Materias:
Meta-Analysis
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9212589/
https://www.ncbi.nlm.nih.gov/pubmed/36785646
http://dx.doi.org/10.1016/j.jointm.2022.05.004

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9212589/
https://www.ncbi.nlm.nih.gov/pubmed/36785646
http://dx.doi.org/10.1016/j.jointm.2022.05.004

Ejemplares similares